

Federica Perrone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9291443/federica-perrone-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

5,297
citations

38
h-index

70
g-index

114
ext. papers

5,988
ext. citations

5.4
avg. IF

4.73
L-index

#	Paper	IF	Citations
114	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102583	2.2	4
113	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	9
112	Peritoneal Mesothelioma: Disease Biology and Patterns of Peritoneal Dissemination 2020 , 117-129		0
111	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	14
110	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020 , 33, 217-227	9.8	8
109	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019 , 46, 507-514	1.6	4
108	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 435-443	5.9	5
107	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2858	4.9	26
106	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019 , 90, 94-101	4.4	7
105	Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
104	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 34-43.e6	3.8	5
103	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018 , 104, 213-220	1.7	2
102	In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. <i>Human Pathology</i> , 2018 , 74, 32-42	3.7	14
101	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e403-e410	3.3	5
100	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018 , 121, 348-356	5.6	47
99	Novel intra-genic large deletions of CTNBN1 gene identified in WT desmoid-type fibromatosis. <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 495-503	5	13
98	Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017 , 3, 139-152	5.3	16

97	Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed E-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 31-47	5.1	23
96	E-catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017 , 11, 1495-1507	7.9	16
95	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017 , 2017, 6870614	3.2	2
94	Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2017 , 16, e191-e198	3.8	9
93	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 231-6	3.3	30
92	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016 , 69, 158-165	7.5	44
91	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , 2016 , 6, 963-71	24.4	71
90	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016 , 22, 3961-70	12.9	53
89	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016 , 14, 125	8.5	26
88	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016 , 38, 724-31	4.2	82
87	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 451-61	5.1	2
86	Reproducibility between messenger RNA real-time polymerase chain reaction and messenger RNA in situ hybridization in oropharyngeal squamous cell carcinoma patients. <i>Human Pathology</i> , 2016 , 47, 157-8	3.7	3
85	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 718-728	8.9	14
84	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016 , 34, 236-42	4.3	20
83	Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 337-43	5	18
82	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 74362-74379	3.3	104
81	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. <i>Oncotarget</i> , 2016 , 7, 75503-75517	3.3	15
80	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016 , 7, 4428-41	3.3	62

79	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016 , 7, 3947-65	3.3	27
78	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. <i>Oncotarget</i> , 2016 , 7, 12731-47	3.3	66
77	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016 , 58, e4-5	4.4	2
76	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 651-62	5.1	13
75	AKT1 and BRAF mutations in pediatric aggressive fibromatosis. <i>Cancer Medicine</i> , 2016 , 5, 1204-13	4.8	20
74	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015 , 75, 1205-15	10.1	63
73	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. <i>European Journal of Cancer</i> , 2015 , 51, 473-481	7.5	12
72	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
71	Peritoneal Mesothelioma. <i>Updates in Surgery Series</i> , 2015 , 243-254	0.1	
70	Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015 , 9, 389-97	7.9	103
69	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 734-45	3.3	6
68	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1560-9	8.9	21
67	Challenging Lung Carcinoma with Coexistent Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1500-2	8.9	13
66	Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. <i>Medical Oncology</i> , 2015 , 32, 182	3.7	18
65	Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2015 , 87, 204-6	5.9	4
64	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation. <i>Histopathology</i> , 2014 , 64, 1014-26	7.3	15
63	Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. <i>British Journal of Cancer</i> , 2014 , 110, 1001-7	8.7	105
62	Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. <i>Annals of Oncology</i> , 2014 , 25, 404-8	10.3	51

61	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014 , 25, 694-699	10.3	27
60	Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection. <i>Tumori</i> , 2014 , 100, 115-121	1.7	24
59	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. <i>PLoS ONE</i> , 2014 , 9, e92147	3.7	17
58	FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. <i>Oncologist</i> , 2014 , 19, 845-50	5.7	37
57	TP53 mutations in advanced colorectal cancer: the dark side of the moon. <i>Oncology</i> , 2014 , 86, 289-94	3.6	8
56	Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 136-48	1.2	6
55	Frequent mutation and nuclear localization of Eatenin in sertoli cell tumors of the testis. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 66-71	6.7	43
54	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 678-82	4.6	17
53	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. <i>Targeted Oncology</i> , 2014 , 9, 155-62	5	23
52	Circulating free DNA in a screening program for early colorectal cancer detection. <i>Tumori</i> , 2014 , 100, 115-21	1.7	24
51	BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. <i>Tumori</i> , 2014 , 100, 315-20	1.7	5
50	Role of BAX for outcome prediction in gastrointestinal malignancies. <i>Medical Oncology</i> , 2013 , 30, 610	3.7	7
49	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. <i>Clinical and Translational Oncology</i> , 2013 , 15, 582-6	3.6	2
48	Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. <i>Annals of Surgical Oncology</i> , 2013 , 20, 4096-102	3.1	132
47	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013 , 49, 413-9	4.4	32
46	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013 , 93, 1232-40	5.9	17
45	DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 23-37	5.7	37
44	Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1098-103	4.6	22

43	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. <i>Cancer</i> , 2013 , 119, 3696-702	6.4	122
42	Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. <i>Translational Oncology</i> , 2012 , 5, 155-9	4.9	13
41	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e226-8	4.5	7
40	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012 , 77, 507-14	5.9	54
39	miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. <i>Molecular Cancer Research</i> , 2012 , 10, 504-15	6.6	110
38	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. <i>Autophagy</i> , 2012 , 8, 1185-96	10.2	43
37	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012 , 23, 1832-7	10.3	82
36	Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 774-7; author reply 777-8	6.7	56
35	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011 , 458, 497-503	5.1	6
34	Intestinal type adenocarcinoma of the ethmoid sinus in wood and leather workers: a retrospective study of 153 cases. <i>Head and Neck</i> , 2011 , 33, 535-42	4.2	45
33	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1886-93	10.3	19
32	TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 761-6	2.2	92
31	Targeted therapies: the rare cancer paradigm. <i>Molecular Oncology</i> , 2010 , 4, 19-37	7.9	33
30	Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. <i>European Journal of Cancer</i> , 2010 , 46, 2837-48	7.5	26
29	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2009 , 20, 84-90	10.3	327
28	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009 , 45, 574-8	4.4	150
27	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009 , 45, 986-90	4.4	111
26	Integrative approach for prioritizing cancer genes in sporadic colon cancer. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 953-62	5	42

25	Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1053-9	4	32
24	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. <i>Neuro-Oncology</i> , 2009 , 11, 725-36	1	63
23	EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. <i>American Journal of Pathology</i> , 2009 , 174, 661-70	5.8	261
22	Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed Patients. <i>Translational Oncology</i> , 2009 , 2, 84-8	4.9	8
21	PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. <i>Cellular Signalling</i> , 2008 , 20, 872-83	4.9	37
20	FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. <i>Current Cancer Drug Targets</i> , 2008 , 8, 342-8	2.8	11
19	TP53 mutations in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1194; author reply 1195	59.2	1
18	Clear cell adenocarcinoma of the colon is a unique morphological variant of intestinal carcinoma: case report with molecular analysis. <i>World Journal of Gastroenterology</i> , 2008 , 14, 6575-7	5.6	12
17	Genetic Markers in Sporadic Tumors 2008 , 43-84		2
16	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007 , 109, 2461-5	6.4	28
15	Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report. <i>Acta Cytologica</i> , 2007 , 51, 589-93	3	14
14	Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. <i>Clinical Cancer Research</i> , 2006 , 12, 6920-8	12.9	119
13	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5630-6	2.2	531
12	Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y). <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1467-73	6.1	15
11	Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006 , 28, 909-15	4.2	29
10	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6643-51	12.9	133
9	Re: Oda et al. Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. <i>J Pathol</i> 2005;207:410-421. <i>Journal of Pathology</i> , 2006 , 209, 281; author reply 282	9.4	1
8	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. <i>Cancer</i> , 2005 , 104, 159-69	6.4	53

7	BRAF alterations are associated with complex mutational profiles in malignant melanoma. <i>Oncogene</i> , 2004 , 23, 5968-77	9.2	168
6	TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>International Journal of Cancer</i> , 2003 , 105, 196-203	7.5	79
5	Elevated risk for MPNST in NF1 microdeletion patients. <i>American Journal of Human Genetics</i> , 2003 , 72, 1288-92	11	230
4	p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 4132-8	12.9	63
3	Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 34 archival cases. <i>Laboratory Investigation</i> , 2002 , 82, 609-18	5.9	31
2	Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. <i>Laboratory Investigation</i> , 2001 , 81, 833-44	5.9	107
1	Prognostic significance of the CaMBr1 antigen on breast carcinoma: relevance of the type of recognised glycoconjugate. <i>European Journal of Cancer</i> , 1993 , 29A, 2113-7	7.5	23